首页> 外文期刊>American Journal of Clinical Oncology: Cancer Clinical Trials >Observation versus adjuvant radiation or chemotherapy in the management of stage i seminoma: Clinical outcomes and prognostic factors for relapse in a large us cohort
【24h】

Observation versus adjuvant radiation or chemotherapy in the management of stage i seminoma: Clinical outcomes and prognostic factors for relapse in a large us cohort

机译:观察与辅助放疗或化疗在I期精原细胞瘤的治疗中:美国一大群患者的临床结局和复发的预后因素

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: The management of stage I seminoma has evolved over the past 20 years. Contemporary management options after orchiectomy include adjuvant radiation, adjuvant chemotherapy, and observation. This analysis defines the experience at Kaiser Permanente Southern California from 1990 to 2010. We examined outcomes for stage I seminoma patients and reviewed prognostic factors for recurrence in those managed with observation. MATERIALS AND METHODS: This is a retrospective study of 502 stage I seminoma patients who underwent orchiectomy from 1990 to 2010. Outcomes examined were relapse-free survival (RFS), overall survival (OS), and cause-specific survival (CSS). Risk factors for recurrence evaluated were age, preoperative hCG elevation, preoperative LDH elevation, tumor size, lymphovascular invasion, rete testis invasion, epididymis invasion, and invasion through the tunica albuginea. RESULTS: Among radiation patients, 5-year RFS was 97.2%, OS was 98.0%, and CSS was 99.3%. Among chemotherapy patients, 2-year RFS was 98.3% and OS and CSS were 100%. Among observation patients, 5-year RFS was 89.2%, OS was 98.8%, and CSS was 100%. There was no difference in OS or CSS among the groups. RFS was significantly lower for observation patients. Among observation patients, univariate analysis identified tumor size, lymphovascular invasion, and rete testis invasion as risk factors for relapse. No factors were significant on multivariate analysis. CONCLUSIONS: Our data show that adjuvant radiation and chemotherapy yield similar outcomes in the management of stage I seminoma. Observation results in a lower RFS, but patients who relapse can be salvaged; OS and CSS are not affected.
机译:目的:在过去的20年中,对I期精原细胞瘤的治疗已有所发展。睾丸切除术后的当代治疗选择包括辅助放疗,辅助化疗和观察。该分析定义了1990年至2010年在南加州凯撒永久医院的经验。我们检查了I期精原细胞瘤患者的结局,并回顾了观察治疗后复发的预后因素。材料与方法:这是一项对1990年至2010年接受睾丸切除术的502例I期精原细胞瘤患者的回顾性研究。检查的结果为无复发生存期(RFS),总生存期(OS)和特定原因生存期(CSS)。评估复发的危险因素是年龄,术前hCG升高,术前LDH升高,肿瘤大小,淋巴管浸润,直肠睾丸浸润,附睾浸润以及通过白膜浸润。结果:在放射线患者中,5年RFS为97.2%,OS为98.0%,CSS为99.3%。在化疗患者中,两年RFS为98.3%,OS和CSS为100%。在观察患者中,五年RFS为89.2%,OS为98.8%,CSS为100%。各组之间的OS或CSS没有区别。观察患者的RFS显着降低。在观察患者中,单因素分析确定了肿瘤大小,淋巴血管浸润和睾丸网状浸润是复发的危险因素。在多变量分析中没有显着因素。结论:我们的数据表明,辅助放疗和化疗在I期精原细胞瘤的治疗中产生相似的结果。观察结果显示RFS较低,但是可以挽救复发的患者;操作系统和CSS不受影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号